Oct. 30 - Quidel revenue up 276% | Medtronic, DOJ reach $9.2M settlement | Stryker, Globus forge on with surgical robots
Medtronic to pay $9.2M to settle DOJ influence, kickback allegations; Stryker, NuVasive, Globus forge on with surgical robots through COVID-19; Illumina defends Grail valuation amid much cheaper Exact-Thrive deal; Medtronic acquires thyroid surgery tech in 7th tuck-in deal of 2020
The medtech giant is accused of offering "lavish" benefits in promoting a certain infusion pump to a South Dakota neurosurgeon, and misreporting those payments under a required CMS program.
Despite worries that the pandemic's financial strain on customers may slow adoption of the expensive tools for knee, hip and spine surgery, device makers' Q3 reports reveal momentum.
The biotech defended its $8 billion purchase price against Exact Sciences' $2.15 billion cancer screening takeout agreement announced this week, arguing Grail has more data and is likely to be first to market.
An addition to the medtech's pandemic-battered ENT business, Ai Biomed's PTeye system won De Novo authorization from FDA in 2018 for its ability to help surgeons spare important calcium-regulating tissue during procedures.
MedTech Dive provides in-depth journalism and insight into the most impactful news and trends shaping medical technology. The newsletters and website cover topics such as medical devices, diagnostics, digital health, regulation/compliance, R&D, M&A and more.
Medtech Dive is a leading publication operated by Industry Dive. Our business journalists spark ideas and shape agendas for 10+ million decision makers in competitive industries.
This email is optimized for display on mobile phones. MedTech Dive: Daily Dive is a product of Industry Dive, Inc.. 1575 Eye St NW, 4th Floor, Washington, DC 20005. We value your privacy. We won't share your email address with anyone else without your permission. This message was sent to edwardlorilla1986.acciyo123@blogger.com. You can unsubscribe or switch to a weekly newsletter subscription anytime. See our full privacy policy.
No comments:
Post a Comment